How to Buy Neurocrine Biosciences Stock
Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders.
Neurocrine Biosciences stock last closed at $135.99, down 1.28% from the previous day, and has increased 32.39% in one year. It has overperformed other stocks in the Drug Manufacturers - Specialty & Generic industry by 0.39 percentage points. Neurocrine Biosciences stock is currently +52.73% from its 52-week low of $89.04, and -8.34% from its 52-week high of $148.37.
There are currently 99.51M NBIX shares outstanding. The market cap of NBIX is $13.53B. In the last 24 hours, 709,152 NBIX shares were traded.
How to Buy Neurocrine Biosciences Stock
Wondering how to invest in Neurocrine Biosciences stock? Here's how.
- Choose where to buy Neurocrine Biosciences stock: You need to pick an online brokerage, but don't worry - we've analyzed dozens of online brokerages and apps to help you choose where to buy Neurocrine Biosciences stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Put funds into your brokerage account: Choose your method of payment and add your details.
- Analyze Neurocrine Biosciences stock: The Neurocrine Biosciences ticker symbol is NBIX. Is Neurocrine Biosciences stock a good investment? Should you buy shares of NBIX? How do NBIX's underlying business fundamentals look? Do top analysts think Neurocrine Biosciences is a good buy? Why has NBIX's stock price moved recently? (Hint: Our stock research website can help you evaluate if NBIX is a good stock to buy).
- Execute your NBIX purchase: Decide if you will purchase NBIX shares at the current market price or use a limit order to purchase NBIX shares at a particular price.
- Get notifications regarding your NBIX position: Create a watchlist to track your investment in Neurocrine Biosciences shares.
Step 1: Choose where to buy Neurocrine Biosciences stock
You need an online brokerage account to access the NASDAQ market and buy NBIX shares.
Our preferred brokerage: eToro
Based on our research, eToro is the best place to buy stocks. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to global markets: From Technology to Real Estate, New York to Tokyo — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by opening an account with eToro now.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've picked your brokerage, the next step is to fill out some personal info so you are able to buy NBIX today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to create your new brokerage account.
- Submit your application by clicking the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you've finished signing up on a good stock buying app, you need to deposit funds:
Watch the tutorial below to see the process of transferring money into your new investment account.
Step 4: Analyze Neurocrine Biosciences stock
Once you have identified the best place to buy Neurocrine Biosciences stock, it's very important to evaluate their stock before you invest, so you actually understand the risk as well as the upside.
Neurocrine Biosciences stock at a glance
NBIX Due Diligence Checks
WallStreetZen was built to help part-time investors perform more in-depth fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on NBIX's stock page.
How is NBIX stock valued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge NBIX's intrinsic value.
Using relative valuations measures:
- NBIX could be overvalued based on its P/E ratio of 53.12x, relative to Drug Manufacturers - Specialty & Generic industry P/E ratio of 33.92x
- NBIX may be overvalued based on its P/B ratio of 6.06x, relative to Drug Manufacturers - Specialty & Generic industry P/B ratio of 2.09x
- NBIX may be undervalued based on its PEG ratio of 0.97x
You can access more valuation analysis on NBIX's stock here.
Is NBIX a healthy company?
Signs that NBIX is financially healthy:
- NBIX profit margin has gone up from 10.4% to 13.2% in the past year.
- Total NBIX debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than long-term liabilities on the NBIX balance sheet.
- There are more short-term assets than short-term liabilities on the NBIX balance sheet.
- NBIX earnings of $336.70M is not enough to cover its interest payments.
- NBIX's operating cash flow of $389.90M allows it to safely service it's debt of $428.40M.
Signs that NBIX is not financially healthy:
- NBIX has a relatively high debt to equity ratio of 0.46.
Is NBIX stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 17 Equities analysts who research NBIX, the consensus analyst rating on Neurocrine Biosciences is a Buy
Please keep in mind that analyst ratings are not recommendations, nor are they investment advice.
Most Recent NBIX Analyst Forecasts
Anupam Rama, a bottom 32% analyst from JP Morgan maintains NBIX with a strong buy rating and raises their NBIX price target from $148.00 to $158.00, on Mar 20, 2024.
David Hoang, a bottom 12% analyst from Citigroup maintains NBIX with a hold rating and lowers their NBIX price target from $141.00 to $140.00, on Feb 8, 2024.
Uy Ear, a bottom 10% analyst from Mizuho maintains NBIX with a hold rating and raises their NBIX price target from $116.00 to $140.00, on Feb 8, 2024.
Chris Shibutani, a top 23% analyst from Goldman Sachs maintains NBIX with a strong buy rating and raises their NBIX price target from $134.00 to $153.00, on Jan 25, 2024.
Carter Gould, a top 22% analyst from Barclays maintains NBIX with a strong buy rating and raises their NBIX price target from $145.00 to $150.00, on Jan 23, 2024.
Barclays's Carter Gould raised their price target on Neurocrine Biosciences (NASDAQ: NBIX) by 3.4% from $145 to $150 on 2024/01/23. The analyst maintained their Strong Buy rating on the stock.
In a U.S. Biopharmaceuticals sector review, Gould contextualized their price target increase on Neurocrine Biosciences by saying that they were positive on most names into Q4 2023 prints but "leaning into recent winners."
According to the analyst, Barclays recommends that Biopharm investors skew their holdings in favor of names with "strong prescription trends, supportive guides and potential upside to 2024 numbers," highlighting Eli Lilly, Merck, AbbVie, and Regeneron.
Conversely, their firm identified Bristol-Myers and Pfizer as the "most challenged names in the group."
You can dive deeper into what analysts are forecasting on the Neurocrine Biosciences stock forecast page.
NBIX Technicals
NBIX Performance Metrics
Last year, NBIX earnings were $249.70M. Over the past 5 year, NBIX's earnings have gone up by 61.92% per year. This was faster than the Drug Manufacturers - Specialty & Generic industry average of -9.47%.
Last year, NBIX revenue was $1.89B. Over the last five year, NBIX's revenue has grown by 33.13% per year. This was faster than the Drug Manufacturers - Specialty & Generic industry average of 30.65%.
Dig into NBIX's earnings and revenue performance here.
Are NBIX executives and large shareholders buying or selling the stock?
In the past year, insiders at NBIX have sold more shares than they have bought.
Eric Benevich, Chief Commercial Officer of NBIX, was the latest NBIX insider to sell. They sold $1,678,665.26 worth of NBIX shares on Apr 15, 2024.
Dig into more about who owns NBIX stock here.
Does NBIX provide a stable income stream?
No, Neurocrine Biosciences doesn't provide an income stream by paying out dividends.
Get analysis from other traders
One of the biggest reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Execute your NBIX purchase
There are two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are generally fine for most investors. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to be certain you're buying or selling at a specific price limit, use a limit order.
Press the Open button and your broker will place the order.
If you require additional help with buying stocks on eToro, click the how to video below:
Step 6: Get notifications regarding your NBIX position
Now that you own some shares in NBIX, you'll want to keep up with your company.
Add NBIX to a watchlist to track the latest developments regarding your NBIX stock.
NBIX Feed
How to Buy Stock in Neurocrine Biosciences
To summarize, here are the 6 steps to buy Neurocrine Biosciences stock:
- Choose where to buy Neurocrine Biosciences stock
- Sign up for your brokerage account
- Put funds into your brokerage account
- Analyze Neurocrine Biosciences stock
- Execute your NBIX purchase
- Get notifications regarding your NBIX position
If you need a online brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you want to get the latest news on your new investment in Neurocrine Biosciences, get started below.
Related Content
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.